The cost-effective alternative
for One Lung Ventilation
VivaSight™ DL is a single-use double lumen tube (DL) that offers a cost-effective way to perform One Lung Ventilation, which increases patient safety.
A health economic study indicates that VivaSight™- DL offers clear financial benefits too.
Study demonstrates savings of
USD 47.65 per procedure
The health economic study (Larsen et al., Aug 2019), which is based on a randomized controlled trial, is the first to compare the costs and effects of a conventional DLT used in combination with a reusable bronchoscope to VivaSight™-DL alone. It concluded that VivaSight™-DL offers a cost-effective alternative for OLV procedures.
Potential gains for institutions of all sizes
According to the study, the incremental savings per OLV procedure were USD 47.65 with VivaSight™-DL (See Table 1). This is equivalent to an annual saving of USD 28,600 (assuming 600 annual procedures). However, even when the number of annual OLV procedures (800, 1000, and 1200 [base-case 600]) is increased, VivaSight™-DL remains cost-effective.
1 Larsen et al. A Cost-Effectiveness Analysis Comparing the VivaSight Double-lumen Tube to a Conventional Double-Lumen Tube in Adult Patients Undergoing Thoracic Surgery Involving One-lung Ventilation. 2019 PharmacoEconomics Open
VivaSight™-DL improves procedure workflow
The tables are the results of a cost-effectiveness analysis, which was based on a randomized control trial (RCT) conducted at a large Danish university hospital where approximately 600 OLV procedures are performed annually.
The RCT was designed with two arms; 22 patients in the conventional DLT arm and 30 in the VivaSight™-DL arm, respectively.
3 reasons Ambu® VivaSight™ 2 DLT reduces hidden costs
The analysis demonstrates that VivaSight 2 DLT reduces costs associated with conventional DLTs, and there are three main reasons for this.
Download the summary of the new health economic study
A Cost-Effectiveness Analysis Comparing the VivaSight Double-lumen Tube and a Conventional Double-lumen Tube in Adult Patients Undergoing Thoracic Surgery Involving One-Lung Ventilation.
Larsen et al., 2019, PharmacoEconomics Open